{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:30:52Z","timestamp":1789536652570,"version":"build-2803163510"},"reference-count":199,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer and cardiovascular disease (CVD) are leading causes of mortality and thus represent major health challenges worldwide. Clinical data suggest that cancer patients have an increased likelihood of developing cardiovascular disease, while epidemiologic studies have shown that patients with cardiovascular disease are also more likely to develop cancer. These observations underscore the increasing importance of studies exploring the mechanisms underlying the interaction between the two diseases. We review their common physiological processes and potential pathophysiological links. We explore the effects of chronic inflammation, oxidative stress, and disorders of fatty acid metabolism in CVD and cancer, and also provide insights into how cancer and its treatments affect heart health, as well as present recent advances in reverse cardio-oncology using a new classification approach.<\/jats:p>","DOI":"10.3389\/fonc.2024.1453090","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:15:38Z","timestamp":1732079738000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Hanwei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035516","article-title":"Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger","volume":"138","author":"Handy","year":"2018","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ihj.2023.09.004","article-title":"Reverse cardio-oncology: A budding concept","volume":"75","author":"Satpathy","year":"2023","journal-title":"Indian Heart J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.727487","article-title":"Cardio-oncology: A myriad of relationships between cardiovascular disease and cancer","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2017.07.005","article-title":"Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases","volume":"264","author":"Damen","year":"2017","journal-title":"Atherosclerosis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102470","article-title":"Alterations of fatty acid profile may contribute to dyslipidemia in chronic kidney disease by influencing hepatocyte metabolism","volume":"20","author":"Czumaj","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.1008","article-title":"Fatty tumor compressing the heart","volume":"151","author":"Mehta","year":"2016","journal-title":"JAMA Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319895415","article-title":"The interplay of endothelial dysfunction, cardiovascular disease, and cancer: What we should know beyond inflammation and oxidative stress","volume":"27","author":"Masoudkabir","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"117080","DOI":"10.1016\/j.lfs.2019.117080","article-title":"Angiopoietin 2 signal complexity in cardiovascular disease and cancer","volume":"239","author":"Nicolini","year":"2019","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.v37.11","article-title":"Fatty acid metabolism disorders and potential therapeutic traditional Chinese medicines in cardiovascular diseases","volume":"37","author":"Liu","year":"2023","journal-title":"Phytother Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000634","article-title":"Monocytes and macrophages in atherogenesis","volume":"30","author":"Amengual","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz058","article-title":"Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology","volume":"115","author":"Libby","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz645","article-title":"Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01426-0","article-title":"Vascular inflammation, cancer, and cardiovascular diseases","volume":"25","author":"Prousi","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106151","article-title":"Nuclear IL-33\/SMAD signaling axis promotes cancer development in chronic inflammation","volume":"40","author":"Park","year":"2021","journal-title":"EMBO J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9294018","DOI":"10.1155\/2017\/9294018","article-title":"Inflammation and cancer: extra- and intracellular determinants of tumor-associated macrophages as tumor promoters","volume":"2017","author":"Szebeni","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"948098","DOI":"10.1155\/2012\/948098","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"Hao","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-030-33330-0_7","article-title":"Inflammation, frailty and cardiovascular disease","volume":"1216","author":"Soysal","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2019.02.022","article-title":"Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease","volume":"493","author":"Ndrepepa","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102813","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.907348","article-title":"Modulation of mTOR signaling in cardiovascular disease to target acute and chronic inflammation","volume":"9","author":"Kaldirim","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/life11020105","article-title":"Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients","volume":"11","author":"Sabbatino","year":"2021","journal-title":"Life (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190215121712","article-title":"Oxidative stress and cancer","volume":"24","author":"Klaunig","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","article-title":"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment","volume":"35","author":"Gupte","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12551-016-0244-4","article-title":"The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases","volume":"9","author":"Deshmukh","year":"2017","journal-title":"Biophys Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12964-023-01398-5","article-title":"Interplay of oxidative stress, cellular communication and signaling pathways in cancer","volume":"22","author":"Iqbal","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1395.001","article-title":"Biological aging is no longer an unsolved problem","volume":"1100","author":"Hayflick","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2009.12.003","article-title":"Therapeutic potential of Ganoderma lucidum (Fr.) P. Karst. against the declined antioxidant status in the mitochondria of post-mitotic tissues of aged mice","volume":"29","author":"Sudheesh","year":"2010","journal-title":"Clin Nutr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3801","article-title":"Cellular mechanisms and physiological consequences of redox-dependent signalling","volume":"15","author":"Holmstrom","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2013.00102","article-title":"Mitochondrial dynamics in the adult cardiomyocytes: which roles for a highly specialized cell","volume":"4","author":"Piquereau","year":"2013","journal-title":"Front Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01283.2006","article-title":"Mitochondrial reactive oxygen species-mediated signaling in endothelial cells","volume":"292","author":"Zhang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.246876","article-title":"The intersection between aging and cardiovascular disease","volume":"110","author":"North","year":"2012","journal-title":"Circ Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.600350","article-title":"Obesity-related fatty acid and cholesterol metabolism in cancer-associated host cells","volume":"8","author":"Ye","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"114613","DOI":"10.1016\/j.ejmech.2022.114613","article-title":"Emerging roles of fatty acid metabolism in cancer and their targeted drug development","volume":"240","author":"An","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"101706","DOI":"10.1016\/j.arr.2022.101706","article-title":"Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases","volume":"81","author":"Hu","year":"2022","journal-title":"Ageing Res Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2015.12.007","article-title":"The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease","volume":"36","author":"Ruiz-Nunez","year":"2016","journal-title":"J Nutr Biochem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01223-1","article-title":"Fatty acid metabolism and cancer immunotherapy","volume":"24","author":"Luo","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60813-1","article-title":"The global obesity pandemic: shaped by global drivers and local environments","volume":"378","author":"Swinburn","year":"2011","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00941-09","article-title":"Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain","volume":"29","author":"Oneyama","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.11.006","article-title":"Steroid hormone receptors in prostate cancer: a hard habit to break","volume":"16","author":"Attard","year":"2009","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.metabol.2019.06.005","article-title":"Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency","volume":"98","author":"Altamimi","year":"2019","journal-title":"Metabolism"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00310-6","article-title":"Ketone bodies for the starving heart","volume":"2","author":"Schulze","year":"2020","journal-title":"Nat Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01967-8","article-title":"Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy","volume":"40","author":"Davila-Roman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.02.018","article-title":"Metabolic manipulation in ischaemic heart disease, a novel approach to treatment","volume":"25","author":"Lee","year":"2004","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1113\/jphysiol.2003.055095","article-title":"Energy metabolism in heart failure","volume":"555","author":"Ventura-Clapier","year":"2004","journal-title":"J Physiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/cvr\/cvr274","article-title":"Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress","volume":"93","author":"Dai","year":"2012","journal-title":"Cardiovasc Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960120610","article-title":"Cardiac manifestations of noncardiac tumors. Part II: Direct effects","volume":"12","author":"Weinberg","year":"1989","journal-title":"Clin Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2324709620923237","DOI":"10.1177\/2324709620923237","article-title":"Poorly differentiated breast adenocarcinoma as a rare cause of right ventricular outflow tract compression: case report and review of the literature","volume":"8","author":"Long","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960130510","article-title":"External compression by metastatic squamous cell carcinoma: a rare cause of left main coronary artery narrowing","volume":"13","author":"Weinberg","year":"1990","journal-title":"Clin Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048655","article-title":"Crosstalk between the heart and cancer: beyond drug toxicity","volume":"142","author":"Moslehi","year":"2020","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082224","article-title":"Cardiotoxicity, cardioprotection, and prognosis in survivors of anticancer treatment undergoing cardiac surgery: unmet needs","volume":"15","author":"Palmieri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-017-0601-x","article-title":"Cancer as a risk factor for cardiovascular disease","volume":"19","author":"Giza","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"Demers","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/HCO.0000000000000878","article-title":"Coronary artery disease in patients with cancer: challenges and opportunities for improvement","volume":"36","author":"Carrillo-Estrada","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"394740","DOI":"10.4061\/2011\/394740","article-title":"Arterial and venous thrombosis in cancer patients","volume":"2011","author":"Blann","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-21-00875","article-title":"Features of atherosclerosis in patients with angina and no obstructive coronary artery disease","volume":"18","author":"Pellegrini","year":"2022","journal-title":"EuroIntervention"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/joim.2015.278.issue-5","article-title":"Detecting the vulnerable plaque in patients","volume":"278","author":"Goncalves","year":"2015","journal-title":"J Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.07.121","article-title":"Identifying and treating vulnerable atherosclerotic plaques","volume":"205","author":"Ambrose","year":"2023","journal-title":"Am J Cardiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.074","article-title":"Atherothrombosis and high-risk plaque: part I: evolving concepts","volume":"46","author":"Fuster","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001226","article-title":"Cardiotoxicity of chemotherapeutic drugs: an update and future perspectives","volume":"80","author":"Bannister","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v97:11","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.2019.102.issue-6","article-title":"Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification","volume":"102","author":"Ferraro","year":"2019","journal-title":"Eur J Haematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05703-5","article-title":"Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients","volume":"182","author":"Cho","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219873014","article-title":"Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines","volume":"26","author":"Mort","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Simunek","year":"2009","journal-title":"Pharmacol Rep"},{"key":"B72","article-title":"Effect of anthracycline antibiotics on oxygen radical formation in rat heart","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res"},{"key":"B73","article-title":"Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin, and carboquone in NAD(P)H-microsome system","volume":"68","author":"Sato","year":"1977","journal-title":"Gan"},{"key":"B74","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0006-291X(77)80048-X","article-title":"Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin","volume":"77","author":"Goodman","year":"1977","journal-title":"Biochem Biophys Res Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490502601","article-title":"Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury","volume":"32","author":"Chaiswing","year":"2004","journal-title":"Toxicol Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0724rev","article-title":"The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage","volume":"18","author":"Fogli","year":"2004","journal-title":"FASEB J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bph.v174.21","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.09.053","article-title":"Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine","volume":"49","author":"Yla-Herttuala","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-Based cohort study","volume":"165","author":"Dahlen","year":"2016","journal-title":"Ann Intern Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"B95","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200328200","article-title":"c-Raf\/MEK\/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells","volume":"277","author":"Iijima","year":"2002","journal-title":"J Biol Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","author":"Bueno","year":"2000","journal-title":"EMBO J"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.5783","article-title":"Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy","volume":"272","author":"Sheng","year":"1997","journal-title":"J Biol Chem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0528-2","article-title":"The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity","volume":"61","author":"Swift","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B104","article-title":"Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin","volume":"61","author":"Zhou","year":"2001","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"119760","DOI":"10.1016\/j.lfs.2021.119760","article-title":"An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity","volume":"280","author":"Anjos","year":"2021","journal-title":"Life Sci"},{"key":"B107","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781337","article-title":"An immunocompetent microphysiological system to simultaneously investigate effects of anti-tumor natural killer cells on tumor and cardiac microtissues","volume":"12","author":"Nguyen","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-002954","article-title":"Immune checkpoint inhibitors: current status","author":"Palma Dos Reis","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010020","article-title":"Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management","volume":"9","author":"Burns","year":"2021","journal-title":"Diseases"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of contemporary anticancer immunotherapy","volume":"22","author":"Dal\u2019bo","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"key":"B136","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11864-021-00845-0","article-title":"Circulating biomarkers for cardiotoxicity risk prediction","volume":"22","author":"Gong","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ccc.2020.08.003","article-title":"Toxicities associated with immunotherapy and approach to cardiotoxicity with novel cancer therapies","volume":"37","author":"Gutierrez","year":"2021","journal-title":"Crit Care Clin"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.07.014","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy","volume":"50","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies","volume":"23","author":"Stein-Merlob","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2019.09.002","article-title":"Cardiotoxicity of mediastinal radiotherapy","volume":"24","author":"Ratosa","year":"2019","journal-title":"Rep Pract Oncol Radiother"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.867479","article-title":"Cardiovascular magnetic resonance in early detection of radiation associated cardiotoxicity with chest radiation","volume":"9","author":"Vallabhaneni","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/path.v249.4","article-title":"Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease","volume":"249","author":"Dukinfield","year":"2019","journal-title":"J Pathol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600141","article-title":"Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo","volume":"86","author":"Buerkle","year":"2002","journal-title":"Br J Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-127480","article-title":"Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy","volume":"23","author":"Johnston","year":"2009","journal-title":"FASEB J"},{"key":"B149","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00395-016-0598-6","article-title":"Role of integrins in mediating cardiac fibroblast-cardiomyocyte cross talk: a dynamic relationship in cardiac biology and pathophysiology","volume":"112","author":"Civitarese","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2463","article-title":"Cardiac dysfunction promotes cancer progression via multiple secreted factors","volume":"82","author":"Awwad","year":"2022","journal-title":"Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.066911","article-title":"Small extracellular vesicles from infarcted and failing heart accelerate tumor growth","volume":"149","author":"Caller","year":"2024","journal-title":"Circulation"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071108","article-title":"Cardiac remodeling in the absence of cardiac contractile dysfunction is sufficient to promote cancer progression","volume":"11","author":"Awwad","year":"2022","journal-title":"Cells"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068396","article-title":"Adult cardiac expression of the activating transcription factor 3, ATF3, promotes ventricular hypertrophy","volume":"8","author":"Koren","year":"2013","journal-title":"PloS One"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.154","article-title":"Epidemiology of cardiovascular disease in young individuals","volume":"15","author":"Andersson","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-023-04680-9","article-title":"CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology","volume":"22","author":"Yang","year":"2024","journal-title":"J Transl Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3726","article-title":"The tumor metabolic microenvironment: lessons from lactate","volume":"79","author":"Garcia-Canaveras","year":"2019","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.04.004","article-title":"Exosomes in cancer development, metastasis, and immunity","volume":"1871","author":"Zhang","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.v53.11","article-title":"microRNA exchange via extracellular vesicles in cancer","volume":"53","author":"Vu","year":"2020","journal-title":"Cell Prolif"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2014.00061","article-title":"Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases","volume":"2","author":"Katoh","year":"2014","journal-title":"Front Cell Dev Biol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.2019.23.issue-4","article-title":"Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p\/PTEN\/PI3K\/AKT signalling pathway in gastric cancer","volume":"23","author":"Li","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1038\/emm.2015.126","article-title":"ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K\/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells","volume":"48","author":"Baik","year":"2016","journal-title":"Exp Mol Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3746","article-title":"miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN\/SMAD4 expression","volume":"49","author":"Ma","year":"2016","journal-title":"Int J Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28518","article-title":"PI3K\/AKT pathway activation in bladder carcinogenesis","volume":"134","author":"Calderaro","year":"2014","journal-title":"Int J Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-019-1177-0","article-title":"LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells","volume":"38","author":"Li","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000004778","article-title":"Propofol affects non-small-cell lung cancer cell biology by regulating the miR-21\/PTEN\/AKT pathway in vitro and in vivo","volume":"131","author":"Zheng","year":"2020","journal-title":"Anesth Analg"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.02.049","article-title":"Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN\/PI3K\/Akt pathways","volume":"221","author":"Liu","year":"2019","journal-title":"Life Sci"},{"key":"B171","doi-asserted-by":"publisher","first-page":"121036","DOI":"10.1016\/j.biomaterials.2021.121036","article-title":"Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy","volume":"276","author":"Liu","year":"2021","journal-title":"Biomaterials"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","first-page":"109111","DOI":"10.1016\/j.biopha.2019.109111","article-title":"MiR-25-3p promotes Malignant phenotypes of retinoblastoma by regulating PTEN\/Akt pathway","volume":"118","author":"Wan","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3751","article-title":"Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN\/PI3K\/Akt\/Bad signaling pathway","volume":"49","author":"Feng","year":"2016","journal-title":"Int J Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01450-5","article-title":"High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN\/Akt pathway in hepatocellular carcinoma","volume":"39","author":"Yang","year":"2020","journal-title":"Oncogene"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3999","article-title":"MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN\/PI3K\/AKT signaling pathway in non-small cell lung cancer metastasis","volume":"51","author":"Lu","year":"2017","journal-title":"Int J Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.661602","article-title":"Exosomal miR-92b-3p promotes chemoresistance of small cell lung cancer through the PTEN\/AKT pathway","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.119","article-title":"MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K\/Akt pathway in breast cancer","volume":"8","author":"Li","year":"2017","journal-title":"Cell Death Dis"},{"key":"B179","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-015-0592-z","article-title":"MiR-106b induces cell radioresistance via the PTEN\/PI3K\/AKT pathways and p21 in colorectal cancer","volume":"13","author":"Zheng","year":"2015","journal-title":"J Transl Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-019-1040-0","article-title":"Circular RNA circSLC8A1 acts as a sponge of miR-130b\/miR-494 in suppressing bladder cancer progression via regulating PTEN","volume":"18","author":"Lu","year":"2019","journal-title":"Mol Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1159\/000500605","article-title":"miR-130b promotes sunitinib resistance through regulation of PTEN in renal cell carcinoma","volume":"97","author":"Sekino","year":"2019","journal-title":"Oncology"},{"key":"B182","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/cbf.v36.4","article-title":"MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt\/beta-catenin pathway","volume":"36","author":"Zhang","year":"2018","journal-title":"Cell Biochem Funct"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0088-9","article-title":"MicroRNA-146b promotes PI3K\/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN","volume":"37","author":"Ramirez-Moya","year":"2018","journal-title":"Oncogene"},{"key":"B184","doi-asserted-by":"publisher","first-page":"109675","DOI":"10.1016\/j.cellsig.2020.109675","article-title":"MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN\/PI3K\/AKT pathway","volume":"73","author":"Yang","year":"2020","journal-title":"Cell Signal"},{"key":"B185","doi-asserted-by":"publisher","first-page":"a000141","DOI":"10.1101\/cshperspect.a000141","article-title":"NF-kappaB as a critical link between inflammation and cancer","volume":"1","author":"Karin","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gde.2008.01.020","article-title":"NF-kappaB and cancer-identifying targets and mechanisms","volume":"18","author":"Naugler","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00546","article-title":"MicroRNA roles in the nuclear factor kappa B signaling pathway in cancer","volume":"9","author":"Wu","year":"2018","journal-title":"Front Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"120722","DOI":"10.1016\/j.lfs.2022.120722","article-title":"miR-16-5p regulates aerobic glycolysis and tumorigenesis of NSCLC cells via LDH-A\/lactate\/NF-kappaB signaling","volume":"304","author":"Arora","year":"2022","journal-title":"Life Sci"},{"key":"B189","doi-asserted-by":"publisher","first-page":"39001","DOI":"10.1038\/srep39001","article-title":"MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S236514","article-title":"miR-423 promotes breast cancer invasion by activating NF-kappaB signaling","volume":"13","author":"Dai","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvab030","article-title":"Circulating microRNA-210 concentrations in patients with acute heart failure: data from the akershus cardiac examination 2 study","volume":"67","author":"Rutkovskiy","year":"2021","journal-title":"Clin Chem"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.10.011","article-title":"The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL","volume":"7","author":"Wang","year":"2013","journal-title":"Mol Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24698","article-title":"miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma","volume":"55","author":"Razumilava","year":"2012","journal-title":"Hepatology"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2278-y","article-title":"A clinical and biological perspective of human myeloid-derived suppressor cells in cancer","volume":"73","author":"Shipp","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B196","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"B197","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-023-01336-4","article-title":"Exosomes secreted from cardiomyocytes suppress the sensitivity of tumor ferroptosis in ischemic heart failure","volume":"8","author":"Yuan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B198","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaccao.2023.10.002","article-title":"Heart failure post-myocardial infarction promotes mammary tumor growth through the NGF-TRKA pathway","volume":"6","author":"Tani","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1453090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:15:48Z","timestamp":1732079748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1453090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":199,"alternative-id":["10.3389\/fonc.2024.1453090"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1453090","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"article-number":"1453090"}}